CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 8, 2013--
(OTC: OVSC), a life sciences company focused on the discovery,
development and commercialization of new treatments for infertility,
announced today the appointment of Harald F. Stock, Ph.D., Chief
Executive Officer of the Grünenthal Group, to its Board of Directors.
“Harald joins our Board at a time when OvaScience continues to achieve
its goals towards developing new infertility treatments for the U.S.
market, while evaluating multiple commercial opportunities outside the
U.S.,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of
OvaScience. “The global fertility market is nearly 10 times larger than
the U.S. alone, and growing rapidly. Harald’s expertise and success
commercializing products in global healthcare markets will be important
to OvaScience as we advance our ex-U.S. strategy.”
Since 2009, Mr. Stock has served as Chief Executive Officer of the
Grünenthal Group, an international research-based pharmaceutical company
headquartered in Germany. Prior to joining Grünenthal, he was Chairman
and Managing Director of the German DePuy Group, the Orthopaedics
Division of Johnson & Johnson. Previously, he held various positions of
increasing responsibilities in local and global functions and corporate
divisions of the Roche Group until 2005, when he was appointed Senior
Vice President of the Global Near Patient Testing business based in
Graz, Austria. Mr. Stock is a Board Member at the European Federation of
Pharmaceutical Industries and Associations (efpia) and immatics
biotechnologies GmbH. He also previously served as Vice-Chairman of the
Supervisory Board of PAION AG, was Board Observer of ConforMIS, Inc. and
represented Johnson & Johnson on the Board of BVMed, the German Medical
Technology Industry Association. Mr. Stock holds a Ph.D. in inorganic
chemistry from the University of Heidelberg.
“OvaScience’s unique approach to developing treatments for infertility
may offer new solutions to address the increasing rate of female
infertility in the U.S. and abroad,” said Mr. Stock. “I look forward to
helping OvaScience bring these new potential therapies to patients
throughout the world.”
OvaScience (OTC: OVSC) is a life sciences company focused on the
discovery, development and commercialization of new treatments for
infertility. The Company’s patented technology is based on the discovery
of egg precursor cells (EggPCSM), which are found in the
ovaries. By applying proprietary technology to identify and purify
EggPCs, AUGMENTSM aims to improve egg quality and increase
the success of in vitro fertilization (IVF). OvaScience’s team of
scientists, physicians and advisers includes recognized leaders in the
field of reproductive medicine. For more information, please visit www.ovascience.com.
Any statements in this press release about OvaScience’s strategy,
future plans, prospects and future expectations constitute
forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by such
forward-looking statements. OvaScience anticipates that subsequent
events and developments will cause its views to change. While OvaScience
may elect to update these forward-looking statements in the future, it
specifically disclaims any obligation to do so.
Source: OvaScience, Inc.
Theresa McNeely, 617-299-7356